SMARCA4 and neoplasm: Future studies examining the combination of novel inhibitors of KRAS or of epigenetic regulators in combination with energy stress agents and/or targeted therapies may prove an effective strategy for targeting tumours for LKB1/KRASG12C or LKB1/BRG1 co-mutated tumours.